Geh et al illustrated that neutrophils with a dual role would transform to the anti-tumor phenotype N1 when TGF-β was suppressed.[74] Linde et al[72] eradicated solid and metastatic tumors by stimulating neutrophil activation, recruitment, and proliferation using neutrophil activation therapy, which was composed of tumor necrosis factor (TNF), anti-CD40 monoclonal antibody, and tumor-specific binding antibody. Here, TGFB1 is linked to neoplasm.